Literature DB >> 7999874

Lean body mass by Dual Energy X-ray Absorptiometry (DEXA) and by urine and dialysate creatinine recovery in CAPD and pre-dialysis patients compared to normal subjects.

P K Nielsen1, J Ladefoged, K Olgaard.   

Abstract

The urinary creatinine excretion rate is a function of the muscle mass which, in normal subjects, is shown to be correlated with lean body mass. Dual Energy X-ray Absorptiometry (DEXA) has been shown to correlate well with other methods for the measurement of body composition. The purpose of the present study was to compare estimates of lean body mass (LBM) by DEXA scan with urine and dialysate creatinine recovery in uremic patients and in normal subjects. We included 63 normal subjects with a creatinine clearance of 60-120 mL/min, 30 uremic predialysis patients with creatinine clearance below 30 mL/min, and 20 continuous ambulatory peritoneal dialysis (CAPD) patients. LBM was measured by DEXA scan on the same day as urine collection and was estimated from creatinine recovery with and without correction for extrarenal creatinine clearance. Results from the normal subjects showed no difference in estimates of LBM by the different methods but, in predialysis and CAPD patients, a significant difference between methods of estimating LBM was found, even when correction for extrarenal clearance in uremic patients was performed. In normal subjects: DEXA 43.6 kg versus creatinine excretion 43.2 kg (NS). In predialysis patients: DEXA 47.8 kg versus 37.6 kg (p < 0.001) corrected 44.8 kg (p < 0.05). In CAPD patients: DEXA 47.2 kg versus 32 kg (p < 0.001) corrected 42.6 kg (p < 0.05). In conclusion, the urine and dialysate creatinine excretion is an inaccurate estimate of LBM, but reflects the muscle mass and, in that respect, is an important tool in the nutritional evaluation of uremic patients.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7999874

Source DB:  PubMed          Journal:  Adv Perit Dial        ISSN: 1197-8554


  6 in total

1.  Urinary creatinine excretion, bioelectrical impedance analysis, and clinical outcomes in patients with CKD: the CRIC study.

Authors:  F Perry Wilson; Dawei Xie; Amanda H Anderson; Mary B Leonard; Peter P Reese; Patrice Delafontaine; Edward Horwitz; Radhakrishna Kallem; Sankar Navaneethan; Akinlolu Ojo; Anna C Porter; James H Sondheimer; H Lee Sweeney; Raymond R Townsend; Harold I Feldman
Journal:  Clin J Am Soc Nephrol       Date:  2014-11-07       Impact factor: 8.237

2.  Urine creatinine excretion and clinical outcomes in CKD.

Authors:  Lucia Di Micco; Robert Ross Quinn; Paul Everett Ronksley; Vincenzo Bellizzi; Adriane Marlene Lewin; Bruno Cianciaruso; Pietro Ravani
Journal:  Clin J Am Soc Nephrol       Date:  2013-10-24       Impact factor: 8.237

3.  Can bone loss be reversed by antithyroid drug therapy in premenopausal women with Graves' disease?

Authors:  Tina Z Belsing; Charlotte Tofteng; Bente L Langdahl; Peder Charles; Ulla Feldt-Rasmussen
Journal:  Nutr Metab (Lond)       Date:  2010-09-01       Impact factor: 4.169

4.  Cystatin C and Muscle Mass in Patients With Heart Failure.

Authors:  Juan B Ivey-Miranda; Lesley A Inker; Matthew Griffin; Veena Rao; Christopher Maulion; Jeffrey M Turner; F Perry Wilson; W H Wilson Tang; Andrew S Levey; Jeffrey M Testani
Journal:  J Card Fail       Date:  2020-08-01       Impact factor: 5.712

5.  Reproducibility of serial creatinine excretion measurements in peritoneal dialysis.

Authors:  Zhi Xu; Glen H Murata; Yijuan Sun; Robert H Glew; Clifford Qualls; Darlene Vigil; Karen S Servilla; Thomas A Golper; Antonios H Tzamaloukas
Journal:  World J Nephrol       Date:  2017-07-06

6.  Cardiorenal syndrome in thalassemia patients.

Authors:  Sorasak Makmettakul; Adisak Tantiworawit; Arintaya Phrommintikul; Pokpong Piriyakhuntorn; Thanawat Rattanathammethee; Sasinee Hantrakool; Chatree Chai-Adisaksopha; Ekarat Rattarittamrong; Lalita Norasetthada; Kanda Fanhchaksai; Pimlak Charoenkwan; Suree Lekawanvijit
Journal:  BMC Nephrol       Date:  2020-08-03       Impact factor: 2.388

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.